Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | OH2 |
Synonyms | |
Therapy Description |
OH2 is an oncolytic herpes simplex virus-2 (HSV-2) engineered to include deletions in the viral genes ICP34.5 and ICP47, and to express human granulocyte macrophage colony stimulating factor (GM-CSF), which may lead to the activation of anti-tumor immune response and tumor cell killing (PMID: 32055679, PMID: 29872496). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
OH2 | OH-2|OH 2|oHSV-2-expressing GM-CSF OH2 | OH2 is an oncolytic herpes simplex virus-2 (HSV-2) engineered to include deletions in the viral genes ICP34.5 and ICP47, and to express human granulocyte macrophage colony stimulating factor (GM-CSF), which may lead to the activation of anti-tumor immune response and tumor cell killing (PMID: 32055679, PMID: 29872496). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | esophageal cancer | predicted - sensitive | OH2 | Case Reports/Case Series | Actionable | In a Phase I/II trial, OH2 treatment in a CD274 (PD-L1)-positive (TPS=3) metastatic esophageal cancer patient led to an immune partial response 5.44 months after treatment initiation, followed by discontinuation of treatment, and an ongoing response lasting over 14.03 months (PMID: 33837053). | 33837053 |
CD274 positive | rectum cancer | predicted - sensitive | OH2 | Case Reports/Case Series | Actionable | In a Phase I/II trial, a patient with CD274 (PD-L1)-positive (TPS=3) metastatic rectal cancer treated with OH2 in a liver metastasis achieved a partial response with reduced size of the injected and non-injected liver lesions 6.89 months after treatment initiation and discontinued treatment but maintained an ongoing response lasting over 11.25 months (PMID: 33837053). | 33837053 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|